Results 41 to 50 of about 22,351 (243)

Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

Neurology, 2021
Objective To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included pregnancies conceived after December 31, 2010, in women with relapsing-remitting MS or ...
W. Yeh, P. A. Widyastuti, A. van der Walt, J. Stankovich, E. Havrdová, D. Horáková, Karolina Vodehnalova, S. Ozakbas, S. Eichau, P. Duquette, T. Kalincik, F. Patti, C. Boz, M. Terzi, B. Yamout, J. Lechner-Scott, P. Sola, O. Skibina, M. Barnett, M. Onofrj, M. Sá, P. Mccombe, P. Grammond, R. Ampapa, F. Grand'Maison, R. Bergamaschi, D. Spitaleri, V. van Pesch, E. Cartechini, S. Hodgkinson, A. Soysal, A. Saiz, M. Gresle, T. Uher, D. Maimone, R. Turkoglu, R. Hupperts, M. Amato, F. Granella, C. Oreja-Guevara, A. Altıntaş, R. Macdonell, T. Castillo-Triviño, H. Butzkueven, R. Alroughani, V. Jokubaitis   +45 more
semanticscholar   +1 more source

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

bioRxiv, 2022
Multiple sclerosis (MS) is an immune-mediated demyelinating disease that alters central nervous system (CNS) functions. Relapsing-remitting MS (RRMS) is the most common form, which can transform into secondary-progressive MS (SPMS) that is associated ...
Y. Kihara, Yunjiao Zhu, Deepa Jonnalagadda, W. Romanow, Carter R. Palmer, Benjamin Siddoway, R. Rivera, Ranjan Dutta, B. Trapp, Jerold Chun   +9 more
semanticscholar   +1 more source

Fingolimod ameliorates schizophrenia‐like cognitive impairments induced by phencyclidine in male rats

British Journal of Pharmacology, 2022
Improvement of cognitive deficits in schizophrenia remains an unmet need owing to the lack of new therapies and drugs. Recent studies have reported that fingolimod, an immunomodulatory drug for treating multiple sclerosis, demonstrates anti‐inflammatory ...
Xueli Yu, Xueyu Qi, Long Wei, Lian-sheng Zhao, W. Deng, Wan-jun Guo, Qiang Wang, Xiao-hong Ma, Xun Hu, Peiyan Ni, Tao Li   +10 more
semanticscholar   +1 more source

Cryptococcal Meningitis Reported With Fingolimod Treatment

Neurology: Neuroimmunology & Neuroinflammation, 2022
Background and Objectives To describe the characteristics of patients with MS reporting cryptococcal meningitis (CM) while treated with fingolimod. Methods The Novartis safety database was searched for cases with CM between January 26, 2006, and February
Maurizio Del Poeta, B. J. Ward, B. Greenberg, B. Hemmer, Bruce A. C. Cree, Sreelatha Komatireddy, Jitendriya Mishra, Roseanne Sullivan, Ajay Kilaru, A. Moore, T. Hach, J. Berger   +11 more
semanticscholar   +1 more source

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study

, 2017
Objectives: Adherence to multiple sclerosis (MS) treatment is essential to optimize the likelihood of full treatment effect. This prospective, observational, single-center cohort study investigated adherence to fingolimod over the 2 years following ...
Michael Coslovsky, Ivo Abraham, Abraham, Ivo, Zimmer, Andrea, Décard, Bernhard F, Andrea Zimmer, Bernhard F Décard, Coslovsky, Michael   +7 more
core   +2 more sources

Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis

Neurobiology of Disease, 2015
Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system (CNS) leading to functional deficits. The remyelination process is mediated by oligodendrocyte progenitor cells (OPCs).
Jing Zhang, Zheng Gang Zhang, Yi Li, Xiaoshuang Ding, Xia Shang, Mei Lu, Stanton B. Elias, Michael Chopp   +7 more
doaj   +1 more source

The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia

Journal of Neuroinflammation, 2021
Background The role of the immune system in stroke is well-recognised. Fingolimod, an immunomodulatory agent licensed for the management of relapsing-remitting multiple sclerosis, has been shown to provide benefit in rodent models of stroke.
Kyle Malone, Andrea C. Diaz Diaz, Jennifer A. Shearer, Anne C. Moore, Christian Waeber   +4 more
doaj   +1 more source

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Journal of Neurology, 2022
Objective To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany. Methods Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventional real ...
T. Ziemssen, M. Lang, S. Schmidt, H. Albrecht, L. Klotz, J. Haas, Christoph Lassek, S. Lang, V. E. Winkelmann, Benjamin Ettle, U. Schulze-Topphoff   +10 more
semanticscholar   +1 more source

Cardiovascular effects of fingolimod: Relevance, detection and approach

Revista Portuguesa de Cardiologia, 2015
Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial ...
Carlos Aguiar, Sónia Batista, Ricardo Pacheco   +2 more
doaj   +1 more source

Fingolimod Inhibits Inflammation but Exacerbates Brain Edema in the Acute Phases of Cerebral Ischemia in Diabetic Mice

Frontiers in Neuroscience, 2020
Background and Purpose: Diabetes mellitus increases stroke incidence and mortality and hampers functional recovery after stroke. Fingolimod has been shown to improve neurofunctional recovery and reduce brain infarction after ischemic injury in mice ...
Wanlu Li, Tingting He, Tingting He, Lu Jiang, Rubing Shi, Yaying Song, Yaying Song, Muyassar Mamtilahun, Yuanyuan Ma, Yuanyuan Ma, Zhijun Zhang, Yaohui Tang, Guo-Yuan Yang, Guo-Yuan Yang, Yongting Wang   +14 more
doaj   +1 more source